What Adiuvo Diagnostics does

Adiuvo Diagnostics Private Limited is a Chennai-based medical device company founded in 2015 that has developed a single commercial product — the Illuminate BIO, a handheld wound assessment device combining multispectral autofluorescence imaging with AI/ML algorithms to detect and map bacterial load in wounds (at a threshold of ≥10⁴ CFU/g) in real time, without dyes or reagents. The technology is positioned for point-of-care use in chronic wound management, including diabetic foot ulcers, skin and soft tissue infections, leprosy leg ulcers, and post-mastectomy wound monitoring, with stated future applications in skin health assessment and cancer diagnostics. The device holds CDSCO regulatory clearance for clinical use in India, and the company's R&D unit is DSIR-certified.

The business model is hardware sales of the Illuminate BIO device to wound care clinicians, hospitals, and clinics via a direct, demo-driven enterprise sales motion. Pricing is quote-based and not publicly disclosed. The company operates from a single facility in the Golden Jubilee Biopark at SIPCOT IT Park, Siruseri, Chennai, with 11-50 employees led by Founder & CEO Geethanjali Radhakrishnan, CTO Dr. Bala Pesala, and COO Mukund Ramamurthi, supported by a Clinical Advisory Board chaired by Prof. Dr. Samir Brahmachari. Commercial sales are limited to India, despite a stated international patent portfolio across more than 20 countries. Support from Qualcomm's QDIC/QWEIN programmes and MedTech Innovator indicates participation in deep-tech and medtech accelerator ecosystems, but no venture funding rounds with material equity raises have been disclosed.

The company faces material near-term headwinds: in early 2026, India's CGPDTM revoked its foundational Indian Patent No. 323440 following a Post Grant Opposition by MolecuLight Corp., and a US ITC investigation was instituted against Adiuvo and Kent Imaging over alleged infringement of US Patent No. 10,438,356. These regulatory and IP actions constrain both its domestic patent position and any US market entry, creating significant risk that must be weighed against the device's clinical validation, regulatory clearance in India, and single-product commercialization.

Name

Adiuvo Diagnostics

Legal name

Adiuvo Diagnostics Private Limited

Website

https://adiuvodiagnostics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Adiuvo Diagnostics is a Chennai-based medical device company that has developed the Illuminate BIO handheld wound assessment device, combining multispectral autofluorescence imaging with AI to detect bacterial load in wounds for clinicians and hospitals in India.

Ownership category

akta.pro rank

Product category

Medical Diagnostic Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Optical Instruments & Lenses (3827)

akta.pro primary industry

SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)

akta.pro secondary industries

Wound Care & Diabetic Foot Infection (HLAKAGAK), Wound Care & Ulcer Management (HLAKACAN)

Keywords

• Wound diagnostics devices
• Autofluorescence imaging systems
• AI wound assessment
• Bacterial detection medical devices
• Point-of-care diagnostics

Headquarters

HQ city

Chennai

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Illuminate BIO Device Sales: The company generates revenue primarily through the sale of its Illuminate BIO handheld wound assessment device. The device combines autofluorescence imaging with AI analysis for real-time bacterial detection in wounds. As a medical device with CDSCO clearance, it is sold directly to healthcare institutions for clinical use.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Adiuvo Diagnostics develops and sells Illuminate BIO, a handheld, AI-powered wound assessment medical device that uses multispectral autofluorescence imaging to instantly map elevated bacterial load (≥10⁴ CFU/g) in wounds. The device enables clinicians to visualize bioburden, monitor wound progression, and make evidence-based treatment decisions at the point of care without dyes or reagents, and is sold to hospitals and clinics in India under CDSCO regulatory clearance.

Product overview

Adiuvo Diagnostics is a technology-based social enterprise that has developed a single unified product offering: Illuminate BIO. This handheld wound assessment device combines multispectral autofluorescence imaging with AI and machine learning to deliver rapid, label-free diagnostics for wound infection detection. The device enables clinicians to visualize hidden bacterial load in wounds, track wound progression over time, and generate evidence-based clinical documentation. Applications extend to pathogen detection, skin health evaluation, and cancer diagnostics. The technology is designed for point-of-care use in low-resource settings, requiring no dyes or reagents.

Differentiator

Problem solved

Functional benefit

Brands

• Illuminate BIO: AI-powered handheld wound assessment device using autofluorescence technology for real-time bacterial load mapping in wounds

Products and services

• Illuminate BIO Handheld, next-generation AI-powered wound assessment device that uses multispectral autofluorescence imaging to instantly map elevated bacterial load (≥10⁴ CFU/g) in wounds. Enables clinicians to visualize bioburden, monitor wound progression, track treatment effectiveness, and make evidence-based decisions at the point of care without dyes or reagents. CDSCO-cleared for clinical use in India and targeted at hospitals, wound care centers, and clinics managing diabetic foot ulcers, skin and soft tissue infections, and post-surgical wounds.

Quantifiable outcome

• Detection threshold of ≥10⁴ CFU/g for bacterial presence
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Kent Imaging: Kent Imaging develops near-infrared spectroscopic imaging (SnapshotNIR) for tissue oxygenation and wound healing assessment, and sells the SnapshotGLO fluorescence product co-developed with Adiuvo. Directly comparable technology and use case.
• Spectral AI: Spectral AI's DeepView platform uses AI-powered multispectral imaging to predict wound healing and burn assessment. Directly comparable AI+imaging approach for wound diagnostics, though focused on healing prediction rather than bacterial detection.
• HyperMed Imaging: HyperMed offers hyperspectral imaging devices (HyperView) for tissue oxygenation and wound perfusion assessment. Comparable handheld imaging approach applied to wound care diagnostics, though using hyperspectral rather than autofluorescence.
• MolecuLight Corp. MolecuLight is the leading commercial fluorescence imaging platform for wound bacterial detection (iDX, MolecuLight i:X, MolecuLight DX). Directly comparable to Adiuvo's Illuminate BIO as both target real-time, point-of-care bacterial bioburden visualization in chronic wounds using autofluorescence imaging.

Broad incumbents

• Tissue Analytics (a Net Health company): Net Health's Tissue Analytics platform combines AI-powered wound imaging, documentation, and EHR integration for hospitals and wound clinics. Adjacent to Adiuvo's clinical documentation value proposition though primarily software-based rather than fluorescence-based.
• Bruker Corporation: Bruker manufactures advanced optical and fluorescence imaging instruments (e.g., fluorescence microscopy and preclinical imaging). Broader incumbent in fluorescence/optical instrumentation that intersects with the underlying imaging technology Adiuvo uses.

Emerging players

• Swift Medical: Swift Medical provides AI-powered smartphone wound imaging and documentation software for wound care clinicians. Comparable end customer (wound care specialists) and AI imaging approach, though delivered via smartphone camera rather than dedicated fluorescence hardware.
• WoundVision (now part of MolecuLight ecosystem): WoundVision has offered fluorescence imaging solutions for wound assessment; technology and use case overlap with Adiuvo's fluorescence-based bioburden detection.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/adiuvo-diagnostics-pvt-ltd
• Instagraminstagram.com/adiuvo_diagnostics2015
• Xx.com/AdiuvoDiag
• Facebookfacebook.com/adiuvodiagnostics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adiuvo Diagnostics